Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2023-11-16 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
MaxCyte Joins the Alliance for mRNA Medicines
Regulatory Filings Classification · 1% confidence The document is a press release issued via the RNS (Regulatory News Service) platform regarding MaxCyte, Inc. joining the Alliance for mRNA Medicines as a founding member. It is a corporate announcement of a strategic partnership/membership, which does not fall into specific financial reporting categories like 10-K, IR, or ER. As it is a general corporate announcement distributed via a regulatory channel, it is best classified under the fallback category for regulatory announcements.
2023-11-16 English
Regulatory Filings 2023
Regulatory Filings
2023-11-14 English
Filing of Form 10-Q
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. stating that they have filed their Form 10-Q for the quarterly period ended September 30, 2023. It provides links to where the actual report can be found on the SEC website and the company's investor relations page. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2023-11-09 English
Third Quarter Results
Earnings Release Classification · 1% confidence The document is a press release from MaxCyte, Inc. announcing its financial results for the third quarter ended September 30, 2023. It includes key financial highlights, revenue guidance, and a summary of financial performance, which are characteristic of an Earnings Release. It is not a full quarterly report (10-Q) or an annual report (10-K), but rather the initial announcement of these results. Q3 2023
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-08 English
8-K
Regulatory Filings
2023-11-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.